Compare NEO & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEO | OPK |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1999 | 1995 |
| Metric | NEO | OPK |
|---|---|---|
| Price | $11.87 | $1.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $12.56 | $2.28 |
| AVG Volume (30 Days) | 1.8M | ★ 2.8M |
| Earning Date | 10-28-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,162,000.00 | $642,067,000.00 |
| Revenue This Year | $10.90 | N/A |
| Revenue Next Year | $9.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.10 | N/A |
| 52 Week Low | $4.72 | $1.11 |
| 52 Week High | $19.12 | $2.04 |
| Indicator | NEO | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 60.77 | 52.93 |
| Support Level | $11.59 | $1.28 |
| Resistance Level | $12.26 | $1.35 |
| Average True Range (ATR) | 0.42 | 0.05 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 49.80 | 68.30 |
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.